A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies

Trial Profile

A Phase I/II, Multicenter, Open-label Study of MAK683 in Adult Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Dec 2017

At a glance

  • Drugs MAK 683 (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Gastric cancer; Nasopharyngeal cancer; Ovarian cancer; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Novartis
  • Most Recent Events

    • 14 Mar 2017 Planned primary completion date changed from 5 Aug 2019 to 8 Feb 2018.
    • 22 Nov 2016 Planned End Date changed from 1 Jul 2019 to 1 Aug 2019.
    • 22 Nov 2016 Planned primary completion date changed from 1 Jul 2019 to 1 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top